These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21821981)

  • 1. [Therapy for malignancies and inflammatory disorders by modulating human dendritic cell functions].
    Kadowaki N; Kitawaki T; Hirai M
    Rinsho Ketsueki; 2011 Jul; 52(7):497-504. PubMed ID: 21821981
    [No Abstract]   [Full Text] [Related]  

  • 2. A phase I/IIa clinical trial of immunotherapy for elderly patients with acute myeloid leukaemia using dendritic cells co-pulsed with WT1 peptide and zoledronate.
    Kitawaki T; Kadowaki N; Fukunaga K; Kasai Y; Maekawa T; Ohmori K; Kondo T; Maekawa R; Takahara M; Nieda M; Kuzushima K; Ishikawa T; Uchiyama T
    Br J Haematol; 2011 Jun; 153(6):796-9. PubMed ID: 21477159
    [No Abstract]   [Full Text] [Related]  

  • 3. [Immunotherapy and cell therapy for myeloid leukemia].
    Yasukawa M
    Nihon Rinsho; 2009 Oct; 67(10):1938-43. PubMed ID: 19860194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current progress in the development of a cell-based vaccine for the immunotherapy of acute myeloid leukemia.
    Klammer M; Roddie PH
    Expert Rev Vaccines; 2006 Apr; 5(2):211-22. PubMed ID: 16608421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [WT1 peptide-based immunotherapy].
    Sugiyama H
    Nihon Rinsho; 2005 Jun; 63(6):1101-9. PubMed ID: 15948398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy Targeting WT1: Designing a Protocol for WT1 Peptide-Based Cancer Vaccine.
    Nishida S; Sugiyama H
    Methods Mol Biol; 2016; 1467():221-32. PubMed ID: 27417973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of chronic myelogenous leukemia.
    Dietz AB; Litzow MR; Gastineau DA; Vuk-Pavlović S
    Croat Med J; 2001 Aug; 42(4):428-35. PubMed ID: 11471194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental production of clinical-grade dendritic cell vaccine for acute myeloid leukemia.
    Tan YF; Sim GC; Habsah A; Leong CF; Cheong SK
    Malays J Pathol; 2008 Dec; 30(2):73-9. PubMed ID: 19291915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dendritic cell-based cancer immunotherapy].
    Aruga A
    Nihon Rinsho; 2010 Jun; 68(6):1107-10. PubMed ID: 20535963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cell vaccines in acute leukaemia.
    Duncan C; Roddie H
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):521-41. PubMed ID: 18790453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
    Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
    J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Harnessing myeloid dendritic cell subsets in novel cancer immunotherapy].
    Ueno H; Fay J; Palucka AK; Banchereau J
    Rinsho Ketsueki; 2011 Jul; 52(7):505-13. PubMed ID: 21821982
    [No Abstract]   [Full Text] [Related]  

  • 13. [WT1 Class I Peptide/WT1 Class II Peptide Pulsed Dendritic Cell Therapy Efficacy in 60 Patients with a Wide Range of Advanced Cancers].
    Kato Y
    Gan To Kagaku Ryoho; 2016 Oct; 43(10):1252-1255. PubMed ID: 27760951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: application to active immunotherapy.
    Royer PJ; Bougras G; Ebstein F; Leveque L; Tanguy-Royer S; Simon T; Juge-Morineau N; Chevallier P; Harousseau JL; Gregoire M
    Exp Hematol; 2008 Mar; 36(3):329-39. PubMed ID: 18207305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [WT1 peptide-based immunotherapy for the treatment of malignancies: focusing on hematological neoplasms].
    Oka Y; Tsuboi A; Nishida S; Hosen N; Nakata J; Hashii Y; Maeda T; Oji Y; Kumanogoh A; Sugiyama H
    Rinsho Ketsueki; 2011 May; 52(5):235-42. PubMed ID: 21646768
    [No Abstract]   [Full Text] [Related]  

  • 16. Nonleukemic myeloid dendritic cells obtained from autologous stem cell products elicit antileukemia responses in patients with acute myeloid leukemia.
    Serrano-López J; Sanchez-Garcia J; Serrano J; Alvarez-Rivas MA; Garcia-Castellano JM; Roman-Gomez J; de la Rosa O; Herrera-Arroyo C; Torres-Gomez A
    Transfusion; 2011 Jul; 51(7):1546-55. PubMed ID: 21303373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial.
    Van Driessche A; Van de Velde AL; Nijs G; Braeckman T; Stein B; De Vries JM; Berneman ZN; Van Tendeloo VF
    Cytotherapy; 2009; 11(5):653-68. PubMed ID: 19530029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell epitope peptide vaccines.
    Elsawa SF; Rodeberg DA; Celis E
    Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Migration of human dendritic cells after injection in patients with metastatic malignancies.
    Morse MA; Coleman RE; Akabani G; Niehaus N; Coleman D; Lyerly HK
    Cancer Res; 1999 Jan; 59(1):56-8. PubMed ID: 9892184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells.
    Breckpot K; Heirman C; Neyns B; Thielemans K
    J Gene Med; 2004 Nov; 6(11):1175-88. PubMed ID: 15468193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.